De‐Iron: a phase 2 trial of the activity and safety of Deferasirox administered at early iron loading in patients with transfusion‐dependent myelodysplastic syndromes

Saved in:
Bibliographic Details
Published in:British journal of haematology 2020-06, Vol.189 (6), p.e237-e240
Main Authors: Killick, Sally, Jackson, Aimee, Coulthard, Helen C., Yap, Christina, Das‐Gupta, Emma, Pennell, Dudley J., Porter, John, Bowen, David, Culligan, Dominic
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Blood Transfusion
Deferasirox - administration & dosage
Deferasirox - adverse effects
Disease-Free Survival
Female
Hematology
Humans
Iron
Male
Middle Aged
Myelodysplastic syndrome
Myelodysplastic Syndromes - blood
Myelodysplastic Syndromes - mortality
Myelodysplastic Syndromes - therapy
Prospective Studies
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3539-b59ae9909c40c56a19380a624f60570cfd4d184e39fc7b39952cf6cea3b9f7003
cites cdi_FETCH-LOGICAL-c3539-b59ae9909c40c56a19380a624f60570cfd4d184e39fc7b39952cf6cea3b9f7003
container_end_page e240
container_issue 6
container_start_page e237
container_title British journal of haematology
container_volume 189
creator Killick, Sally
Jackson, Aimee
Coulthard, Helen C.
Yap, Christina
Das‐Gupta, Emma
Pennell, Dudley J.
Porter, John
Bowen, David
Culligan, Dominic
description
doi_str_mv 10.1111/bjh.16669
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2413483073</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2413483073</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3539-b59ae9909c40c56a19380a624f60570cfd4d184e39fc7b39952cf6cea3b9f7003</originalsourceid><addsrcrecordid>eNp1kU1uFDEQhS0EIpPAggsgS6xYdGK33T9mR34gQZHYwLpVbZcZj7rtxvYQescROAfH4iQYJrCjNlXS-_ReSY-QZ5yd8jJn4257ytu2VQ_Ihou2qWou-UOyYYx1FWeyPyLHKe0Y44I1_DE5ErWQteybDflxiT-_fb-Jwb-iQJctJKQ1zdHBRIOleYsUdHZfXF4peEMTWCxnkS7RYoTkYvhKwczOu5QxoqGQKUKcVlokT6cAxvlP1Hm6QHboc6J3Lm9LBvhk98kFXz4wuKA3RaXzilMwa1omSNlpmlZvYpgxPSGPLEwJn97vE_LxzdWHi-vq9v3bm4vXt5UWjVDV2ChApZjSkummBa5Ez6CtpW1Z0zFtjTS8lyiU1d0olGpqbVuNIEZlO8bECXlx8F1i-LzHlIdd2EdfIodaciF7wTpRqJcHSseQUkQ7LNHNENeBs-F3K0NpZfjTSmGf3zvuxxnNP_JvDQU4OwB3bsL1_07D-bvrg-UvZKGbkA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2413483073</pqid></control><display><type>article</type><title>De‐Iron: a phase 2 trial of the activity and safety of Deferasirox administered at early iron loading in patients with transfusion‐dependent myelodysplastic syndromes</title><source>Wiley</source><creator>Killick, Sally ; Jackson, Aimee ; Coulthard, Helen C. ; Yap, Christina ; Das‐Gupta, Emma ; Pennell, Dudley J. ; Porter, John ; Bowen, David ; Culligan, Dominic</creator><creatorcontrib>Killick, Sally ; Jackson, Aimee ; Coulthard, Helen C. ; Yap, Christina ; Das‐Gupta, Emma ; Pennell, Dudley J. ; Porter, John ; Bowen, David ; Culligan, Dominic</creatorcontrib><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.16669</identifier><identifier>PMID: 32342485</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Aged ; Aged, 80 and over ; Blood Transfusion ; Deferasirox - administration &amp; dosage ; Deferasirox - adverse effects ; Disease-Free Survival ; Female ; Hematology ; Humans ; Iron ; Male ; Middle Aged ; Myelodysplastic syndrome ; Myelodysplastic Syndromes - blood ; Myelodysplastic Syndromes - mortality ; Myelodysplastic Syndromes - therapy ; Prospective Studies ; Survival Rate</subject><ispartof>British journal of haematology, 2020-06, Vol.189 (6), p.e237-e240</ispartof><rights>2020 British Society for Haematology and John Wiley &amp; Sons Ltd</rights><rights>Copyright © 2020 John Wiley &amp; Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3539-b59ae9909c40c56a19380a624f60570cfd4d184e39fc7b39952cf6cea3b9f7003</citedby><cites>FETCH-LOGICAL-c3539-b59ae9909c40c56a19380a624f60570cfd4d184e39fc7b39952cf6cea3b9f7003</cites><orcidid>0000-0003-1495-8001</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32342485$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Killick, Sally</creatorcontrib><creatorcontrib>Jackson, Aimee</creatorcontrib><creatorcontrib>Coulthard, Helen C.</creatorcontrib><creatorcontrib>Yap, Christina</creatorcontrib><creatorcontrib>Das‐Gupta, Emma</creatorcontrib><creatorcontrib>Pennell, Dudley J.</creatorcontrib><creatorcontrib>Porter, John</creatorcontrib><creatorcontrib>Bowen, David</creatorcontrib><creatorcontrib>Culligan, Dominic</creatorcontrib><title>De‐Iron: a phase 2 trial of the activity and safety of Deferasirox administered at early iron loading in patients with transfusion‐dependent myelodysplastic syndromes</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Blood Transfusion</subject><subject>Deferasirox - administration &amp; dosage</subject><subject>Deferasirox - adverse effects</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Iron</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myelodysplastic syndrome</subject><subject>Myelodysplastic Syndromes - blood</subject><subject>Myelodysplastic Syndromes - mortality</subject><subject>Myelodysplastic Syndromes - therapy</subject><subject>Prospective Studies</subject><subject>Survival Rate</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kU1uFDEQhS0EIpPAggsgS6xYdGK33T9mR34gQZHYwLpVbZcZj7rtxvYQescROAfH4iQYJrCjNlXS-_ReSY-QZ5yd8jJn4257ytu2VQ_Ihou2qWou-UOyYYx1FWeyPyLHKe0Y44I1_DE5ErWQteybDflxiT-_fb-Jwb-iQJctJKQ1zdHBRIOleYsUdHZfXF4peEMTWCxnkS7RYoTkYvhKwczOu5QxoqGQKUKcVlokT6cAxvlP1Hm6QHboc6J3Lm9LBvhk98kFXz4wuKA3RaXzilMwa1omSNlpmlZvYpgxPSGPLEwJn97vE_LxzdWHi-vq9v3bm4vXt5UWjVDV2ChApZjSkummBa5Ez6CtpW1Z0zFtjTS8lyiU1d0olGpqbVuNIEZlO8bECXlx8F1i-LzHlIdd2EdfIodaciF7wTpRqJcHSseQUkQ7LNHNENeBs-F3K0NpZfjTSmGf3zvuxxnNP_JvDQU4OwB3bsL1_07D-bvrg-UvZKGbkA</recordid><startdate>202006</startdate><enddate>202006</enddate><creator>Killick, Sally</creator><creator>Jackson, Aimee</creator><creator>Coulthard, Helen C.</creator><creator>Yap, Christina</creator><creator>Das‐Gupta, Emma</creator><creator>Pennell, Dudley J.</creator><creator>Porter, John</creator><creator>Bowen, David</creator><creator>Culligan, Dominic</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><orcidid>https://orcid.org/0000-0003-1495-8001</orcidid></search><sort><creationdate>202006</creationdate><title>De‐Iron: a phase 2 trial of the activity and safety of Deferasirox administered at early iron loading in patients with transfusion‐dependent myelodysplastic syndromes</title><author>Killick, Sally ; Jackson, Aimee ; Coulthard, Helen C. ; Yap, Christina ; Das‐Gupta, Emma ; Pennell, Dudley J. ; Porter, John ; Bowen, David ; Culligan, Dominic</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3539-b59ae9909c40c56a19380a624f60570cfd4d184e39fc7b39952cf6cea3b9f7003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Blood Transfusion</topic><topic>Deferasirox - administration &amp; dosage</topic><topic>Deferasirox - adverse effects</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Iron</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myelodysplastic syndrome</topic><topic>Myelodysplastic Syndromes - blood</topic><topic>Myelodysplastic Syndromes - mortality</topic><topic>Myelodysplastic Syndromes - therapy</topic><topic>Prospective Studies</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Killick, Sally</creatorcontrib><creatorcontrib>Jackson, Aimee</creatorcontrib><creatorcontrib>Coulthard, Helen C.</creatorcontrib><creatorcontrib>Yap, Christina</creatorcontrib><creatorcontrib>Das‐Gupta, Emma</creatorcontrib><creatorcontrib>Pennell, Dudley J.</creatorcontrib><creatorcontrib>Porter, John</creatorcontrib><creatorcontrib>Bowen, David</creatorcontrib><creatorcontrib>Culligan, Dominic</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Killick, Sally</au><au>Jackson, Aimee</au><au>Coulthard, Helen C.</au><au>Yap, Christina</au><au>Das‐Gupta, Emma</au><au>Pennell, Dudley J.</au><au>Porter, John</au><au>Bowen, David</au><au>Culligan, Dominic</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>De‐Iron: a phase 2 trial of the activity and safety of Deferasirox administered at early iron loading in patients with transfusion‐dependent myelodysplastic syndromes</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2020-06</date><risdate>2020</risdate><volume>189</volume><issue>6</issue><spage>e237</spage><epage>e240</epage><pages>e237-e240</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>32342485</pmid><doi>10.1111/bjh.16669</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-1495-8001</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0007-1048
ispartof British journal of haematology, 2020-06, Vol.189 (6), p.e237-e240
issn 0007-1048
1365-2141
language eng
recordid cdi_proquest_journals_2413483073
source Wiley
subjects Aged
Aged, 80 and over
Blood Transfusion
Deferasirox - administration & dosage
Deferasirox - adverse effects
Disease-Free Survival
Female
Hematology
Humans
Iron
Male
Middle Aged
Myelodysplastic syndrome
Myelodysplastic Syndromes - blood
Myelodysplastic Syndromes - mortality
Myelodysplastic Syndromes - therapy
Prospective Studies
Survival Rate
title De‐Iron: a phase 2 trial of the activity and safety of Deferasirox administered at early iron loading in patients with transfusion‐dependent myelodysplastic syndromes
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T14%3A05%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=De%E2%80%90Iron:%20a%20phase%202%20trial%20of%20the%20activity%20and%20safety%20of%20Deferasirox%20administered%20at%20early%20iron%20loading%20in%20patients%20with%20transfusion%E2%80%90dependent%20myelodysplastic%20syndromes&rft.jtitle=British%20journal%20of%20haematology&rft.au=Killick,%20Sally&rft.date=2020-06&rft.volume=189&rft.issue=6&rft.spage=e237&rft.epage=e240&rft.pages=e237-e240&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.16669&rft_dat=%3Cproquest_cross%3E2413483073%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3539-b59ae9909c40c56a19380a624f60570cfd4d184e39fc7b39952cf6cea3b9f7003%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2413483073&rft_id=info:pmid/32342485&rfr_iscdi=true